Immix Biopharma, Inc. (IMMX)

NASDAQ: IMMX · IEX Real-Time Price · USD
1.34
-0.03 (-2.19%)
Nov 25, 2022 4:00 PM EDT - Market closed
-2.19%
Market Cap 19.08M
Revenue (ttm) n/a
Net Income (ttm) -27.19M
Shares Out 13.92M
EPS (ttm) -3.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,649
Open 1.38
Previous Close 1.37
Day's Range 1.34 - 1.38
52-Week Range 0.68 - 8.68
Beta n/a
Analysts Buy
Price Target 5.10 (+280.6%)
Earnings Date Nov 11, 2022

About IMMX

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply... [Read more]

Industry Biotechnology
IPO Date Dec 16, 2021
Employees 2
Stock Exchange NASDAQ
Ticker Symbol IMMX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for IMMX stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 280.60% from the latest price.

Price Target
$5.1
(280.60% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinica...

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/be19ab99-a0c8-4850-a0a4-1592fdc18600

2 weeks ago - GlobeNewsWire

Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquit...

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa

1 month ago - GlobeNewsWire

ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue S...

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/400e1702-f2a3-4d75-bc8a-3554ee8fa7af

1 month ago - GlobeNewsWire

ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/49d68ad5-624b-46b9-8f15-cc07b6717d92

2 months ago - GlobeNewsWire

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sol...

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38fdaa24-38ff-482c-8b72-63baa730a3a2

6 months ago - GlobeNewsWire

Immix Biopharma Announces Share Repurchase Program

LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM tar...

6 months ago - GlobeNewsWire

ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day...

LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting...

7 months ago - GlobeNewsWire

Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/29ada955-df7a-4722-968a-3a3e0fd0d34d

8 months ago - GlobeNewsWire

ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease

A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4733027e-ec5e-4598-9b6e-d5a9c4031c56

9 months ago - GlobeNewsWire

5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI

Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, C...

Other symbols: GTLBTSRI
9 months ago - InvestorPlace

ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022

LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting o...

9 months ago - GlobeNewsWire

ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

An image of IMX-110 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/870f17c2-db33-4a8b-bccd-b09dc60f1e7d.

9 months ago - GlobeNewsWire

Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies

Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own pancreatic cancer and have an intact ...

10 months ago - Benzinga

IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolsterin...

A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d970eaab-d8f9-43e3-b8d9-91a952d18b58

10 months ago - GlobeNewsWire

ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of P...

A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b83a7ede-262b-4777-a2f9-beb13ee761bc

10 months ago - GlobeNewsWire

ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard ...

A graph accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/14a74b9a-30ad-4410-a0d6-9a084753dd4c

10 months ago - GlobeNewsWire

Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders

Los Angeles, CA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM target...

10 months ago - GlobeNewsWire

Why Immix Biopharma Shares Are Rising Today

Immix Biopharma Inc (NASDAQ: IMMX) is trading higher Tuesday on continued momentum after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation for IMX-110 for the treatment of...

10 months ago - Benzinga

IMMX Stock Alert: The Massive FDA Win That Has Immix Biopharma Blasting Higher Today

Immix Biopharma (IMMX) stock is taking off Monday thanks to a Rare Pediatric Disease designation from the U.S. Food and Drug Administration. The post IMMX Stock Alert: The Massive FDA Win That Has Immix...

10 months ago - InvestorPlace

Immix Shares Rally On FDA Rare Pediatric Disease Tag For Cancer Program In Children

The FDA has granted Rare Pediatric Disease (RPD) designation to newly listed Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 for rhabdomyosarcoma, a form of pediatric cancer. IMX-110 is currently being eva...

10 months ago - Benzinga

Immix Biopharma's stock rockets after pediatric cancer treatment granted RPD by the FDA

Shares of Immix Biopharma Inc. IMMX, +9.20% rocketed 66.0% in premarket trading Monday, after the biopharmaceutical company said its IMX-110 was granted Rare Pediatric Disease (RPD) designation by the F...

10 months ago - Market Watch

U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatm...

LOS ANGELES, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting ...

10 months ago - GlobeNewsWire

Immix Biopharma, Inc. Announces Closing of Initial Public Offering

LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM target...

11 months ago - GlobeNewsWire

Immix Biopharma, Inc. Announces Pricing of Initial Public Offering

LOS ANGELES, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting ...

11 months ago - GlobeNewsWire